Randomized trial demonstrates prolonged overall survival with avelumab maintenance in advanced urothelial carcinoma, indicating a valuable post-chemotherapy strategy.
Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number, NCT02603432.).
No takes yet. Share an insight, caveat, or question.
Powles et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: